

UC San Diego

Altman Clinical and Translational Research Institute

May 4, 2022

Phillipp Hartmann
1545 Northrim Court
Unit 269
San Diego, CA 92111

Dear Dr. Hartmann:

Thank you again for applying to the 2022 ACTRI KL2 Career Development Award, and for your patience throughout the process. Your application received an outstanding score among the 33 applicants, and your proposal was selected for funding!

Award Overview: Altman Clinical and Translational Research Institute (ACTRI) will contribute up to [REDACTED]

[REDACTED] Please note the end of the KL2 parent grant is April 30, 2025. As such, we cannot guarantee funding beyond that point. In prior years, we have been able to access unspent funds to continue scholar's appointments. We will be seeking renewal funds from the National Center for Advancing Translational Sciences (NCATS), our parent funder, to complete scholar's third year of funding appointed on the new grant. Scholars progress is reviewed annually.

Start Date: Your grant start date will be determined by 1) the status of your faculty appointment (if not currently appointed as faculty), 2) review and pending approval of your appointment by the NIH (see below), and 3) the timing of available slots. We (Adriana Tremoulet and Colin Depp) would like to meet with you and discuss your preferences for your appointment date and answer any questions you may have.

NIH/ NCATS Prior Approval:

Before we can appoint scholars to the KL2 program and release funding, NIH/NCATS conducts a review as part of Prior Approval. This process can be somewhat lengthy. You will be contacted by our grants management team requesting required materials needed for Prior Approval review.

Prior Approval requirements vary complexity depending IRB approved study risk level. All studies involving human subjects will require IRB approval, the NCATS Prior Approval Addendum, a study timeline, and additional documents based on study risk. Research involving live vertebrate animals require IACUC approval, the NCATS Live Vertebrate Checklist, and the NCATS Vertebrate Animals Section. It is critical that your work with our team to provide these documents in a timely manner.

If your study involves human subjects, please send us your [UCSD official IRB approval letter](#). If you have not done so, we strongly urge you to submit your research protocol to UCSD's IRB for review as soon as possible. Please note you must have the NCATS and IRB approval prior to the distribution of funds. The sooner we can submit these documents to NIH the sooner you can be appointed.

Publications: Publications that result from research utilizing the ACTRI KL2 Program resources should cite the grant as a contributing source of support as follows: "This research was partially supported by the Altman Clinical & Translational Research Institute (ACTRI) at the University of California, San Diego. The ACTRI is funded from awards issued by the National Center for Advancing Translational Sciences, NIH **KL2TR001444**." Altman Clinical and Translational Research Institute, 9500 Gilman Drive, MC 0990, La Jolla, CA. 92093-0990



PEDIATRIC SCIENTIST DEVELOPMENT PROGRAM

Under the aegis of the Association of Medical School Pediatric Department Chairs (AMSPDC)

November 16, 2021

Phillipp Hartmann, MD
8585 Via Mallorca Unit 6
La Jolla, CA 92037

Supported by:

National Institute of Child
Health and Human
Development

American Academy of
Pediatrics

American Pediatric Society

March of Dimes

Burroughs Wellcome Fund

Cystic Fibrosis Foundation

Program Director:
Sallie Permar, MD, PhD

Program Administrator:
Janet Lam, MSW

Weill Cornell Medicine
525 East 68th Street
M-622, Box 225
New York, NY 10065

Phone: 212-746-3394

Email:
jal2059@med.cornell.edu
<https://amspdc-psdp.org/>

Dear Dr. Hartmann,

On behalf of the Steering Committee of the PSDP, I am very pleased to inform you that you have been recommended for a third year in the program for your project titled, "Intestinal Mycobiome in Pediatric Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis." As you know, this third year is funded by your sponsoring department and begins on July 1, 2022.

Your salary will be commensurate with the University of California, San Diego's salary for a Gastroenterology, Hepatology and Nutrition fellow.

We are excited to see the results of your scientific training after three years in the PSDP, and we look forward to helping you launch a rewarding career as a physician-scientist.

With best wishes,

Sallie Permar, MD, PhD
Nancy C. Paduano Professor and Chair
Department of Pediatrics
Pediatrician-in-Chief
NewYork-Presbyterian Komansky Children's Hospital
NewYork-Presbyterian Hospital/ Weill Cornell Medical Center
Email: sallie.permar@med.cornell.edu
Telephone: 212-746-4111

cc:

Gabriel G. Haddad, MD, Nominating and Sponsoring Chair
Bernd Schnabl, MD, Research Mentor
Rob Knight, PhD, Research Co-Mentor
Aleta Gunsul, MPA, Director, Research Business Operations,
Office of Sponsored Research, Weill Cornell Medicine



2022 Pinnacle Research Award in Liver Diseases Grant Agreement

Phillipp Hartmann

Recipient

Role of Candida albicans for the development of non-alcoholic steatohepatitis

Project Title

University of California, San Diego

Sponsoring Institution

Bernd Schnabl

Mentor

The AASLD Foundation has agreed to make a grant to Recipient, which the AASLD Foundation will disburse pursuant to this Agreement. The Parties agree that the Recipient shall expend best scientific efforts to accomplish the aims described in this Agreement and in the Application (attached and incorporated herein), and as approved by the AASLD Foundation. Therefore, in consideration, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, in accepting the Clinical, Translational, and Outcomes Research Award in Liver Diseases (**Award**) from the American Association for the Study of Liver Diseases Foundation (**AASLDF**), the **Recipient** and **University of California, San Diego (Institution)** assume an obligation to expend **Award** funds of

. No additional or indirect costs, registration fees, or travel are covered under this award; it is expected that additional funds are available to the investigator in order to carry out the proposed research. The funds support only the project or research listed in Attachment A of this Grant Agreement. Funds may not be used for capital equipment, directed to other projects, or support institutional functions unrelated to the project.

The Award is awarded to the Recipient and cannot be transferred to another person at the same institution or under the same mentor. Permission for a transfer of mentor or institution must be authorized by AASLDF in advance of the event or the Award will be terminated on the date the Recipient leaves the mentor or ceases to work at the Institution at which the Award was awarded, whichever occurs first.

Award Tenure

The Award will be activated on July 1, 2022, and no funds may be obligated or spent prior to July 1, 2022. Termination date of the award is June 30, 2025, unless the Award is terminated earlier by either the Recipient or AASLDF. No funds may be expended after the June 30, 2025, Termination Date or after the Award is terminated, if such award is prior to the Termination Date.

Definitions

All accounting terms not specifically defined herein shall have the meanings determined by generally accepted accounting principles, consistently applied.

Default shall be as defined below.

Disbursements

Subject to the continued compliance by Recipient and Institution with all of the terms of this Agreement and the Application and any other documents, the continued satisfaction of all conditions precedent to disbursing Grant proceeds under this Agreement, the satisfactory review of any reports due pursuant to this Agreement, the continued non-existence of a Default or any event, circumstance, act or omission which with the giving of notice, the passage of time, or both, would constitute a Default, and the non-existence of a Force Majeure event, AASLDF shall make payment upon receipt of completed required documentation.

All disbursements shall be made directly to **University of California San Diego** by Automatic Clearing House (ACH) transfer.

Conditions for All Disbursements: The obligation of AASLDF to make any disbursement of the Grant is subject to the satisfaction of the following conditions as of the date the disbursement is made:

San Diego Digestive Diseases Research Center (SDDRC)

**Pilot/Feasibility Funding Acknowledgement
(Conditions of Acceptance)**

PI: Hartmann, Phillipp, MD

[REDACTED]

[REDACTED]

[REDACTED]

Award Period: January 1, 2023 – December 31, 2023

PI Contact Information:

[REDACTED]

Department Fund Manager Contact Information:

[REDACTED]

1. At Time of Award:

PI will notify their academic department and Fund Manager about this award. Questions about award management can be addressed to the SDDRC (sddrc@ucsd.edu)

[REDACTED]

2. Regulatory Approvals (check all that apply):

Human Subjects

- ☐ Project does not involve Human Subjects research.
- ☐ Human Subjects research protocol has been approved. Protocol number:
- ☐ Human Subjects research is exempt from IRB review. Protocol number:
- ☐ Human Subjects research protocol approval is pending.

PI agrees to provide SDDRC with IRB approval documentation before commencement of any grant-related research activities.

[REDACTED]

Animal Subjects

- ☐ Project does not involve Vertebrate Animal research.
- ☐ Vertebrate Animal research protocol has been approved. Protocol number:
- ☐ Vertebrate Animal research protocol approval is pending.

PI agrees to provide SDDRC with IACUC approval documentation before commencement of any grant-related research activities.

[REDACTED]